Cardiovascular disease in women: Do we need new diagnostic and therapeutic strategies?


Por: Jiménez-Quevedo P., Alonso-Martin C., Ruiz R.C., Guzmán-Martinez G., Perez M.P., Sambola A.

Publicada: 26 feb 2023 Ahead of Print: 1 feb 2023
Resumen:
Cardiovascular disease (CVD) is the leading cause of death worldwide affecting both sexes equal-ly. However, in comparison to men, in women, it often is underrecognized and undertreated in both primary and secondary prevention settings. It is clear, that in the healthy population, there are profound differences both anatomically and biochemically between women and men, and this may impact how both groups present when they become ill. Moreover, some diseases affect more frequently women than men such as myocardial ischemia or infarction without obstructive coronary disease, Takotsubo syndrome, some atrial arrhythmias, or heart failure with preserved ejection fraction. Therefore, diagnostic and therapeutic strategies that have been established largely on the basis of clinical studies with a predominantly male population must be adapted before being applied to women. There is a paucity of data regarding cardiovascular disease in women. It is inadequate to only perform a subgroup analysis evaluating a specific treatment or invasive technique when women constitute fifty percent of the population. In this regard, this may affect the time of clinical diagnosis and severity assessments of some valvulopathies. In this review, we will focus on the differences in the diagnosis, management, and outcomes for women with the most frequent cardiovascular pathologies including coronary artery disease, arrhythmia, heart failure, and valvopathies. In addition, we will describe diseases that exclusively affect women that are related to pregnancy, and some of them are life-threatening. Although the lack of research on women plays a role in the poorer outcomes in women, especially in ischemic heart disease, some techniques such as transcatheter aortic valve implantation and transcatheter edge-to-edge therapy seem to have better outcomes in women.

Filiaciones:
Jiménez-Quevedo P.:
 IdISSC, Clin San Carlos Univ Hosp, Madrid, Spain

Alonso-Martin C.:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Cardiol, Inst Recerca HSCSP IIb St Pau,Arrhythmia Unit,CIB, Barcelona, Spain

Ruiz R.C.:
 Univ Hosp Fdn Alcorcon, Dept Cardiol, Cardiac Rehabil Unit, Madrid, Spain

Guzmán-Martinez G.:
 La Paz Univ Hosp, Dept Cardiol, IdiPaz, Madrid, Spain

 Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain

 Atrys Hlth, Madrid, Spain

Perez M.P.:
 Univ Hosp Santiago de Compostela, Dept Cardiol, Cardiooncol & Cardiovasc Dis Women Unit, Santiago De Compostela, Spain

Sambola A.:
 Univ Hosp Santiago de Compostela, Dept Cardiol, Cardiooncol & Cardiovasc Dis Women Unit, Santiago De Compostela, Spain

 Univ Autonoma Barcelona, Univ Hosp Vall dHebron, CIBER Cardiovasc Dis CIBER CV, Dept Cardiol, Barcelona, Spain

 Univ Autonoma Barcelona, Univ Hosp Vall dHebron, CIBER Cardiovasc Dis CIBER CV, Res Inst, Barcelona, Spain
ISSN: 00229032
Editorial
POLSKIE TOWARZYSTOWO KARDIOLOGICZNE, UL STAWKI 3 A LOK 1-2, WARSZAWA, POLAND, Polonia
Tipo de documento: Review
Volumen: 81 Número: 4
Páginas: 338-349
WOS Id: 000970263100001
ID de PubMed: 36871309
imagen gold, All Open Access; Gold

MÉTRICAS